If you have been reading about pentadecapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual inspection of dry material |
| Solubility | Soluble in water | Polar aqueous solvent class |
| Typical storage | Minus 20 degrees Celsius, desiccated, dark | Applies to the lyophilized form |
| Purity assessment | Reversed-phase HPLC | Ultraviolet detection, area percent |
| Identity confirmation | Mass spectrometry | Measured mass compared with theoretical value |
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
== Biography == Vincent du Vigneaud was born in Chicago in 1901. Of French descent, he was the son of inventor and mechanic Alfred du Vigneaud and Mary Theresa. He studied at the Schurz High School and completed secondary education in 1918. His interest in sulfur began when he entered high school and his new friends invited him to run chemical experiments on explosives using sulfur. During World War I, senior students were made to work on farms, and du Vigneaud worked near Caledonia, Illinois. There he became an expert in milking cows, which inspired him to become a farmer. However, his elder sister, Beatrice, persuaded him to take up chemistry at the University of Illinois at Urbana-Champaign, after which he enrolled in the chemical engineering course. He later recalled: I found during the first year that it was chemistry rather than engineering that appealed to me most. I switched to a major in chemistry, since I was deeply impressed by the senior student's work, especially in organic chemistry. I also found that I was most interested in those aspects of organic chemistry that had to do with medical substances and began to develop an interest in biochemistry.His interest was aroused by lectures of Carl Shipp Marvel and Howard B. Lewis, whom he remembered as being 'extremely enthusiastic about sulfur." With little support from the family, he found odd jobs to support himself. After receiving his MS in 1924 he joined DuPont. He married Zella Zon Ford, whom he met on June 12, 1924, while working as a waiter during his university course.
== Research == There is evidence that paroxetine may be effective in the treatment of compulsive gambling and hot flashes. Benefits of paroxetine prescription for diabetic neuropathy or chronic tension headache are uncertain. Although the evidence is conflicting, paroxetine may be effective for the treatment of dysthymia, a chronic disorder involving depressive symptoms for most days of the year. There is evidence to support that paroxetine selectively binds to and inhibits G protein-coupled receptor kinase 2 (GRK2) in mice with heart failure. Since GRK2 regulates the activity of the beta adrenergic receptor, which becomes desensitized in cases of heart failure, paroxetine (or a paroxetine derivative) could be used as a heart failure treatment in the future. Paroxetine has been identified as a potential disease-modifying osteoarthritis drug.
== In vitro experiments == An in vitro study of remdesivir assessing antiviral activity against SARS-CoV-2 was performed. Cells were pre-treated with the different doses of remdesivir for 1 hour, and the virus (MOI of 0.05) was subsequently added to allow infection for 2 hours. The results found that remdesivir functioned well as an inhibitor of the infection. The study was published as a letter to the editor, and as such did not undergo peer review.
In Belgium, four patients with severe musculoskeletal infections received bacteriophage therapy with concomitant antibiotics. After a single course of phage therapy, no recurrence of infection occurred and no severe side-effects related to the therapy were detected.
Sources: en.wikipedia.org
=== More examples === acetaldehyde dehydrogenase alcohol dehydrogenase Delta12-fatty acid dehydrogenase glutamate dehydrogenase (an enzyme that can convert glutamate to α-Ketoglutarate and vice versa). lactate dehydrogenase (used to convert NADH back to NAD+ in anaerobic glycolysis, and in the back reaction to produce NADH) pyruvate dehydrogenase (A common enzyme that feeds the TCA Cycle by converting pyruvate to acetyl CoA, using NAD+. In this reaction, the substrate not only is oxidized but also loses a carbon dioxide molecule, and is attached to the CoA coenzyme.) glucose-6-phosphate dehydrogenase (involved in the pentose phosphate pathway, producing NADPH) glyceraldehyde-3-phosphate dehydrogenase (involved in glycolysis, uses NAD+) sorbitol dehydrogenase TCA cycle examples:
== Further reading == Hofmeister F. (1888) Arch. Exptl. Pathol. Pharmakol., 24, 247. Zhang, Y; Cremer, P (December 2006). "Interactions between macromolecules and ions: The Hofmeister series". Current Opinion in Chemical Biology. 10 (6): 658–63. doi:10.1016/j.cbpa.2006.09.020. PMID 17035073. Zhou, Huan-Xiang (October 2005). "Interactions of macromolecules with salt ions: an electrostatic theory for the Hofmeister effect". Proteins: Structure, Function, and Bioinformatics. 61 (1): 69–78. doi:10.1002/prot.20500. PMID 16044460. S2CID 4996928. Tanford C and Reynolds J. (2001) Nature's robots: a history of proteins, Oxford University Press. ISBN 0-19-850466-7 Creighton TE. (1993) Proteins, 2nd ed., W. H. Freeman. ISBN 0-7167-2317-4 Jencks WP. (1969) Catalysis in Chemistry and Enzymology, Dover republication (1987). ISBN 0-486-65460-5 Collins, KD.; Washabaugh, MW. (1985). "The Hofmeister effect and the behaviour of water at interfaces". Q Rev Biophys. 18 (4): 323–422. doi:10.1017/s0033583500005369. PMID 3916340. John Leo, Abernethy (1967). "Franz Hofmeister - The impact of his life and research on chemistry". Journal of Chemical Education. 44 (3): 177–80. Bibcode:1967JChEd..44..177A. doi:10.1021/ed044p177. PMID 5343300.
== Experimental chemistry == Experimental results of the chemistry of dubnium date back to 1974 and 1976. JINR researchers used a thermochromatographic system and concluded that the volatility of dubnium bromide was less than that of niobium bromide and about the same as that of hafnium bromide. It is not certain that the detected fission products confirmed that the parent was indeed element 105. These results may imply that dubnium behaves more like hafnium than niobium. The next studies on the chemistry of dubnium were conducted in 1988, in Berkeley. They examined whether the most stable oxidation state of dubnium in aqueous solution was +5. Dubnium was fumed twice and washed with concentrated nitric acid; sorption of dubnium on glass cover slips was then compared with that of the group 5 elements niobium and tantalum and the group 4 elements zirconium and hafnium produced under similar conditions. The group 5 elements are known to sorb on glass surfaces; the group 4 elements do not. Dubnium was confirmed as a group 5 member. Surprisingly, the behavior on extraction from mixed nitric and hydrofluoric acid solution into methyl isobutyl ketone differed between dubnium, tantalum, and niobium. Dubnium did not extract and its behavior resembled niobium more closely than tantalum, indicating that complexing behavior could not be predicted purely from simple extrapolations of trends within a group in the periodic table. This prompted further exploration of the chemical behavior of complexes of dubnium.
Sources: en.wikipedia.org
The adrenergic receptors were discovered Henry Hallett Dale in 1906 and the α- and β-adrenergic receptors were differentiated by Raymond P. Ahlquist in 1948. In 1967, the β-adrenergic receptors were further differentiated into the β1- and β2-adrenergic receptors by Alonzo M. Lands. The first beta blocker to be developed was dichloroisoprenaline, based on structural modification of the β-adrenergic receptor agonist isoprenaline (isoproterenol). It was described by C. E. Powell and I. H. Slater in 1958. However, dichloroisoprenaline had significant partial agonism and sympathomimetic activity and hence was not a pure antagonist. James Black and John Stephenson described pronethalol (nethalide; ICI-38,174; Alderlin) as a purely antagonistic beta blocker in 1962. But pronethalol suffered from off-target activity and associated side effects and toxicity. As such, it did not enter widespread use and was soon discontinued. In 1964, Black and colleagues published on propranolol (ICI-45,520; Inderal), which did not have the problems of earlier beta blockers. It was introduced for medical use under the brand name Inderal the same year and became the first widely used beta blocker. Since the introduction of propranolol, there have been three generations of beta blockers with different pharmacological properties, with numerous beta blockers having been developed and introduced for medical use.
As such, it appears that there may be species differences in the central penetration of bicalutamide and that the medication does indeed cross the blood–brain barrier and affect central function in humans. This is supported by potential side effects of bicalutamide, in spite of increased testosterone levels, like hot flashes and decreased sexual interest in men. However, a clinical study comparing bicalutamide and flutamide in men found that bicalutamide had less influence on the HPG axis than flutamide, suggesting that bicalutamide might have a limited degree of peripheral selectivity, at least compared to other NSAAs, in humans. Bicalutamide has been identified as a substrate of P-glycoprotein and of the breast cancer resistance protein (BCRP), though not of the multidrug resistance-associated protein 1 (MRP1). This may be involved in tumor resistance to bicalutamide. P-Glycoprotein is also known to play a major role in excluding drugs from the brain due to efflux back across the blood–brain barrier. It is known that there are prominent species differences in the role of P-glycoprotein in limiting permeation of P-glycoprotein substrates across the blood–brain barrier.
The isotopes 284Nh and 283Nh have half-lives of 0.90 and 0.12 seconds respectively. The remaining two isotopes have half-lives between 0.1 and 100 milliseconds: 282Nh has a half-life of 61 milliseconds, and 278Nh, the lightest known nihonium isotope, is also the shortest-lived, with a half-life of 2.0 milliseconds. This rapid increase in the half-lives near the closed neutron shell at N = 184 is seen in roentgenium, copernicium, and nihonium (elements 111 through 113), where each extra neutron so far multiplies the half-life by a factor of 5 to 20. The unknown isotopes in the gap between 278Nh and 282Nh are too heavy to be produced by cold fusion and too light to be produced by hot fusion. The missing 280Nh and 281Nh may be populated as daughters of 284Mc and 285Mc, producible in the 241Am+48Ca reaction, but this has not yet been attempted. Of particular interest is 281Nh, as it is the expected great-granddaughter of 293119, a possible product of the 243Am+54Cr reaction. Production of 282Mc and 283Mc is possible in the 243Am+44Ca reaction (though it has a lower cross-section), and their daughters would be 278Nh (known) and 279Nh. The heavier isotopes 287Nh through 290Nh might be synthesised using charged-particle evaporation, using the 242Pu+48Ca and 244Pu+48Ca reactions where one proton and some neutrons are evaporated.
Sources: en.wikipedia.org
Dry powder is commonly held at minus twenty degrees Celsius, desiccated and away from light. Cold storage slows degradation of the lyophilized material.
Mass spectrometry establishes the molecular mass, and reversed-phase chromatography reports purity. A certificate of analysis typically combines both results.
Solutions degrade faster than the dry powder, particularly at room temperature. Portioning into single-use aliquots and freezing reduces losses from repeated thawing.
Bacteriostatic water or sterile saline is commonly used to dissolve the powder. The choice of solvent affects stability and preservation. Aqueous solutions are kept refrigerated and are not intended for long-term storage.